Thyrocare Technologies (539871) Panoramica del titolo
Thyrocare Technologies Limited fornisce servizi di analisi diagnostica a pazienti, laboratori e ospedali in India. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 1/6 |
| Crescita futura | 5/6 |
| Prestazioni passate | 5/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 4/6 |
539871 Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Thyrocare Technologies Limited
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | ₹565.50 |
| Massimo di 52 settimane | ₹662.00 |
| Minimo di 52 settimane | ₹342.55 |
| Beta | 0.46 |
| Variazione di 1 mese | 1.27% |
| Variazione a 3 mesi | 21.26% |
| Variazione di 1 anno | 34.39% |
| Variazione a 3 anni | 216.63% |
| Variazione a 5 anni | 35.99% |
| Variazione dall'IPO | 174.51% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Aug 15
539871: Fair Outlook As Objects Clause Change And Governance Steps Will Support Confidence
Analysts have lifted their fair value estimate for Thyrocare Technologies from ₹603 to ₹663, as they factor in slightly higher revenue growth assumptions, a marginally lower discount rate, a similar profit margin outlook, and a higher future P/E multiple in their updated model. What's in the News for Thyrocare Technologies Thyrocare Technologies has scheduled a board meeting on Jul 23, 2026 at 14:45 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter ended Jun 30, 2026, along with the limited review report.Aggiornamento narrativa • Jun 19
539871: Expanded Healthcare Objects Clause And New Auditors Will Support Bullish View
Analysts have nudged their fair value estimate for Thyrocare Technologies slightly higher, from ₹600 to ₹603, reflecting updated assumptions around long term profit margins and future P/E expectations. What’s in the News for Thyrocare Technologies A board meeting is scheduled for May 07, 2026 to review and approve the audited standalone and consolidated financial results for the year ended March 31, 2026, and to consider several governance and audit related items (source: Key Developments).Recent updates
Aggiornamento narrativa • Aug 15
539871: Fair Outlook As Objects Clause Change And Governance Steps Will Support Confidence
Analysts have lifted their fair value estimate for Thyrocare Technologies from ₹603 to ₹663, as they factor in slightly higher revenue growth assumptions, a marginally lower discount rate, a similar profit margin outlook, and a higher future P/E multiple in their updated model. What's in the News for Thyrocare Technologies Thyrocare Technologies has scheduled a board meeting on Jul 23, 2026 at 14:45 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter ended Jun 30, 2026, along with the limited review report.Aggiornamento narrativa • Jun 19
539871: Expanded Healthcare Objects Clause And New Auditors Will Support Bullish View
Analysts have nudged their fair value estimate for Thyrocare Technologies slightly higher, from ₹600 to ₹603, reflecting updated assumptions around long term profit margins and future P/E expectations. What’s in the News for Thyrocare Technologies A board meeting is scheduled for May 07, 2026 to review and approve the audited standalone and consolidated financial results for the year ended March 31, 2026, and to consider several governance and audit related items (source: Key Developments).Aggiornamento narrativa • Jun 04
539871: Expanded Healthcare Objects Clause Will Support Bullish Medium Term View
Analysts have maintained their fair value estimate for Thyrocare Technologies at ₹600, with unchanged assumptions on discount rate, revenue growth, profit margin and future P/E. This indicates that the latest review did not alter their fundamental valuation framework for the stock.Aggiornamento narrativa • May 18
539871: Expanded Healthcare Mandate Will Support Bullish Medium Term View
Analysts have lifted their price target on Thyrocare Technologies from ₹571.67 to ₹600.00, and point to updated assumptions around revenue growth, profit margins and a slightly lower future P/E multiple as key drivers of the change. What's in the News The Board has approved changes to the Memorandum of Association to align it with the Companies Act, 2013, including updated references and clauses linked to current regulations (Key Developments).Aggiornamento narrativa • Apr 28
539871: Stable Return Assumptions Will Support Bullish Medium Term View
Analysts have kept Thyrocare Technologies' fair value estimate steady at ₹571.67 per share, with only small tweaks to inputs such as expected revenue growth, profit margin, and future P/E assumptions driving this unchanged price target. Valuation Changes Fair Value: Kept unchanged at ₹571.67 per share, indicating no net impact from the latest input updates.Aggiornamento narrativa • Apr 09
539871: Stable Assumptions And Upcoming Results Will Support Bullish View
Analysts have kept their price target for Thyrocare Technologies steady at ₹571.67, citing largely unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E in their latest update. What's in the News A board meeting is scheduled on January 28, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Aggiornamento narrativa • Mar 25
539871: Stable Assumptions And Upcoming Results Will Support Bullish Outlook
Analysts have kept their price target for Thyrocare Technologies broadly unchanged at around ₹572. This reflects stable assumptions on discount rate, revenue growth, profit margin and future P/E in their valuation work.Aggiornamento narrativa • Mar 11
539871: Steady Assumptions And Upcoming Results Will Support Future Returns
Analysts have kept their price target for Thyrocare Technologies steady at ₹571.67, reflecting largely unchanged views on fair value, discount rate, growth and profit assumptions. What's in the News Board meeting scheduled for January 28, 2026, to review and consider the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Aggiornamento narrativa • Feb 24
539871: Steady Assumptions And Upcoming Results Will Support Future Returns
Analysts have kept their price target for Thyrocare Technologies steady at ₹571.67, reflecting unchanged assumptions on fair value, discount rate, revenue growth, profit margins and future P/E in their updated work. What's in the News A board meeting is scheduled for January 28, 2026, to consider and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Aggiornamento narrativa • Feb 10
539871: Capitalisation Flexibility And Updated Profit Assumptions Will Support Returns
Analysts have slightly revised their price target on Thyrocare Technologies to ₹571.67, reflecting updated assumptions around discount rate, revenue growth, profit margin and future P/E that are now modestly lower than previously assumed. What's in the News Board meeting scheduled on January 28, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Aggiornamento narrativa • Jan 26
539871: Capitalisation Flexibility And Higher Future P/E Will Support Returns
Analysts have nudged their fair value estimate for Thyrocare Technologies higher from ₹560.56 to ₹571.67, reflecting updated views on its long term revenue growth, profit margins and future P/E assumptions. What's in the News A board meeting is scheduled on January 28, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Aggiornamento narrativa • Jan 10
539871: Stock Split And Bonus Share Flexibility Will Support Future Returns
Analysts have lifted their fair value estimate for Thyrocare Technologies from ₹506.67 to ₹560.56, reflecting updated assumptions around revenue growth, profit margins and a higher future P/E multiple. What's in the News Board approval has been sought via a postal ballot dated October 14, 2025 to increase authorised share capital to INR 3,000,000,000, split into 300,000,000 equity shares of INR 10 each, with related changes to the Memorandum and Articles of Association (company filing).Aggiornamento narrativa • Dec 26
539871: Stock Split And Bonus Capacity Will Drive Future Shareholder Returns
Analysts have maintained their price target for Thyrocare Technologies at ₹506.67 per share, reflecting unchanged assumptions on discount rate, revenue growth, profit margins, and future valuation multiples. What's in the News The board approved a proposal to increase authorised share capital and amend the Memorandum of Association and Articles of Association, subject to shareholder approval (Board Meeting, October 14, 2025, Key Developments).Aggiornamento narrativa • Dec 11
539871: Bonus Share And Stock Split Plan Will Drive Future Shareholder Value
Analysts have sharply reduced their price target on Thyrocare Technologies to approximately ₹507 from about ₹1,520. This reflects a recalibrated fair value framework even as underlying assumptions for growth, margins, discount rate and future valuation multiples remain largely unchanged.Aggiornamento narrativa • Nov 27
539871: Upcoming Board Approvals And Dividend Proposals Will Shape Shareholder Value
Analysts have maintained their fair value estimate for Thyrocare Technologies at ₹1,520 per share, citing stable outlooks in revenue growth and profit margins as the key drivers behind the unchanged price target. What's in the News The board meeting on October 14, 2025 considered and approved unaudited financial results for the quarter and half year ended September 30, 2025.Aggiornamento narrativa • Nov 12
539871: Upcoming Board Decisions And Shareholder Actions Will Influence Outlook
Analysts have maintained their price target for Thyrocare Technologies at ₹1,520, citing stable expectations for revenue growth, profit margin, and valuation metrics. What's in the News Special or Extraordinary Shareholders Meeting scheduled for November 16, 2025, to be conducted via postal ballot in India (Key Developments).Aggiornamento narrativa • Oct 29
Upcoming Bonus Shares And Dividend Proposal Will Drive Shareholder Value
Analysts have maintained their price target for Thyrocare Technologies at ₹1,520, citing stable revenue growth projections along with only minor adjustments in profit margin and future valuation metrics. What's in the News The board meeting was held on October 14, 2025 to approve unaudited financial results, consider the declaration of an interim dividend, and review a proposal for the issue of bonus shares (Board Meeting).Aggiornamento narrativa • Oct 15
Franchise Expansion And PharmEasy Partnerships Will Secure Future Success
Analysts have raised their fair value estimate for Thyrocare Technologies from ₹1,355 to ₹1,520. They cite improved profit margins and expectations of sustainable earnings, even though revenue growth is moderating.Aggiornamento narrativa • Sep 05
Franchise Expansion And PharmEasy Partnerships Will Secure Future Success
With both Net Profit Margin and Future P/E ratio remaining stable, analysts have kept Thyrocare Technologies’ fair value unchanged at ₹1355. What's in the News Special/Extraordinary Shareholders Meeting scheduled via postal ballot in India.
Nuova narrativa • Jan 26
Integrating Vimta Labs And Achieving 100% NABL Accreditation Will Position The Company As An Industry Leader
Expanding geographical presence and strategic acquisitions are expected to drive future revenue growth and enhance service offerings.Rendimenti per gli azionisti
| 539871 | IN Healthcare | IN Mercato | |
|---|---|---|---|
| 7D | -9.3% | -0.2% | -0.5% |
| 1Y | 34.4% | 0.8% | 1.7% |
Ritorno vs Industria: 539871 ha superato il Indian Healthcare che ha restituito 0.8 % nell'ultimo anno.
Rendimento vs Mercato: 539871 ha superato il mercato Indian che ha restituito 1.7 % nell'ultimo anno.
Volatilità dei prezzi
| 539871 volatility | |
|---|---|
| 539871 Average Weekly Movement | 6.0% |
| Healthcare Industry Average Movement | 5.6% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
Prezzo delle azioni stabile: 539871 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Indian.
Volatilità nel tempo: La volatilità settimanale ( 6% ) di 539871 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1996 | 1,906 | Rahul Guha | www.thyrocare.com |
Thyrocare Technologies Limited fornisce servizi di analisi diagnostica a pazienti, laboratori e ospedali in India. Opera attraverso tre segmenti: Servizi di analisi diagnostiche, Servizi di imaging e Altri. L'azienda esegue vari test medico-diagnostici e profili di test che si concentrano sulla diagnosi precoce e sulla gestione di disturbi e malattie, tra cui la tiroide, la crescita, il metabolismo, l'autoimmunità, il diabete, l'anemia, il sistema cardiovascolare, l'infertilità e varie malattie infettive.
Thyrocare Technologies Limited Riepilogo dei fondamenti
| 539871 statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | ₹90.01b |
| Utili (TTM) | ₹1.76b |
| Ricavi(TTM) | ₹8.76b |
51.1x
Rapporto P/E10.3x
Rapporto P/S539871 è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| 539871 Conto economico (TTM) | |
|---|---|
| Ricavi | ₹8.76b |
| Costo del fatturato | ₹3.95b |
| Profitto lordo | ₹4.82b |
| Altre spese | ₹3.05b |
| Utili | ₹1.76b |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 11.08 |
| Margine lordo | 54.96% |
| Margine di profitto netto | 20.12% |
| Rapporto debito/patrimonio netto | 8.6% |
Come si è comportato 539871 nel lungo periodo?
Vedi performance storica e confrontoDividendi
1.6%
Rendimento attuale del dividendo91%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/21 18:51 |
| Prezzo dell'azione a fine giornata | 2026/08/21 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Thyrocare Technologies Limited è coperta da 13 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| Hrishikesh Patole | 360 ONE Capital Market Private Limited |
| Rahul Agarwal | CGS International |